Unambiguous Causation

Application Scope of the MBS

Primary Diagnosis

USE CASE

Diagnose causation of acute lower respiratory infections, such as Community Acquired Pneumonia and Exacerbations in patients with Chronic Respiratory Disease.

ADVANTAGES

Providing a sample from the site of infection, allowing for diagnostic results within the "golden" hour, enabling directed therapy in a timely fashion.

VALIDATION

Proof-of-Concept study 2019; Assessment of COPD patients admitted to the hospital with an exacerbation.

The Clinical Sample of Choice for Diagnosing Lung Infections

Better sample, lower burden!​

USE CASE

Early detection of respiratory pathogens in patients with Chronic Respiratory Disease, e.g. CF and COPD.

ADVANTAGES

Easy-of-use and low sampling burden allow for daily or even hourly sampling, enabling health monitoring of the lower respiratory tract and early treatment, avoiding under- or over-treatment and herewith exacerbations.

VALIDATION

Early causation in CF patients; Published in Journal of Breath Research, 2022.

Health Monitoring

Unambiguous Diagnosis is Hampered by Conventional Sampling Methods

Better sample, lower burden!​

Contagiousness

USE CASE

More relevant than ever, safeguarding medical personnel and determining if a patient should be isolated or can go home to recover.

ADVANTAGES

The presence of pathogens, e.g. Mycobacterium tuberculosis or SARS-COV-2, does not determine contagiousness, bio-loaded aerosols do.

VALIDATION

Determining contagiousness of COVID-19 patients by sampling exhaled breath; Published in Scientific Reports, 2022.

Get In touch

Leave us a message

Reinier Postlaan 2, 6525GC Nijmegen, The Netherlands

About

Xheal Diagnostics B.V. is a start-up company and spin-off of the Radboudumc focussed sampling innovations for the lower respiratory tract. Our proprietary exhaled breath sampling technology enables a timely and better diagnosis of lung infections and hence improves patient care.

Xheal Diagnostics 2022 © All Rights Reserved.